-- 据周四在香港交易所发布的公告显示，先声药业（HKG:2096）重新提交的雷德米基巴特（Rademikibart）新药申请已获中国国家药品监督管理局受理。 该药物由先声药业与香港康泰生物制药有限公司联合研发，获准用于治疗成人和青少年特应性皮炎。
Related Articles
Australia
AVITA Medical Names Cary Vance as CEO
AVITA Medical's (RCEL) board appointed Cary Vance as president and chief executive officer, effective immediately after serving as CEO on an interim basis since October, the company said Thursday.The board also named Jan Stern Reed as chairman, with immediate effect, AVITA Medical said.Price: $4.33, Change: $+0.10, Percent Change: +2.36%
$RCEL
Australia
NLIGHT Plans to Expand Operations in Torino, Italy
NLIGHT (LASR) said Thursday it plans to expand its existing facility in Torino, Italy, to meet growing demand for locally assembled directed energy systems.The company said the expansion will enhance its capability to supply high-power laser subsystems and integrated components tailored to regional requirements.The upgraded site will focus on local assembly, testing, and lifecycle support for defense applications in European and Middle Eastern markets, nLIGHT said.Shares of the company were up 3.4% in Thursday trading.Price: $67.15, Change: $+2.18, Percent Change: +3.36%
$LASR
Australia
DoorDash, Lyft Expand Partnership Into Canada
DoorDash (DASH) and Lyft (LYFT) said Thursday they are expanding their partnership into Canada, enhancing the value of DashPass by introducing rideshare savings for members.DashPass is DoorDash's membership program designed to help customers save on everyday purchases, offering free delivery and reduced service fees on eligible orders.The expansion aims to transform DashPass into a broader lifestyle membership and help Lyft reach a new rider base, according to the statement.DashPass members can save on Lyft through upfront discounts on eligible rides, the statement added.Price: $169.50, Change: $+0.16, Percent Change: +0.10%
$DASH$LYFT